But for outcomes in "a patient or two," Alexion Pharmaceuticals Inc.'s top-line results from the trial called Regain with Soliris (eculizumab) in refractory generalized myasthenia gravis (gMG) "would have been very different," CEO David Hallal said, calling the data package available so far "compelling and certainly supportive of the potential efficacy."